Pedro Machado is an Associate Professor & Consultant in Rheumatology and Neuromuscular Diseases at University College London (UCL), University College Hospital (UCH), National Hospital for Neurology and Neurosurgery (NHNN) and Northwick Park Hospital. He is a principal investigator at the UCL Department of Neuromuscular Diseases and at the UCL Centre for Rheumatology. Dr Machado runs both specialist spondyloarthritis (rheumatology department) and myopathy (neuromuscular department) clinics.
His research interests include the investigation of new therapeutic strategies and the assessment and prediction of outcomes in rheumatic diseases, with a focus on muscle diseases and axial spondyloarthritis. More recently he developed an interest in COVID-19, particularly in the outcome of COVID-19 in patients with rheumatic and neuromuscular diseases. His published research work includes the development and validation of the ankylosing spondylitis disease activity score (ASDAS), the study of the relationship between MRI inflammation, MRI fat deposition and progression of structural damage in axial spondyloarthritis (axSpA), the validation of MRI as a biomarker in muscle diseases, and the development of a new therapeutic strategy targeting protein homeostasis in inclusion body myositis (IBM).
He has (co)authored over 150 articles and four book chapters. He has been awarded four fellowships and 13 scientific prizes. He is the chair of the European League Against Rheumatism (EULAR) Standing Committee on Epidemiology and Health Services Research (SCEHSR) and a member of the EULAR Executive Committee, the COVID–19 Global Rheumatology Alliance Steering Committee, the EULAR-COVID-19 Registry steering group, The Assessment of Spondyloarthritis International Society (ASAS), the British Society of Spondyloarthritis (BRITSpA), the British Society of Rheumatology (BSR), The American College of Rheumatology (ACR), The Portuguese Society of Rheumatology (SPR), The International Myositis Assessment & Clinical Studies Group (IMACS), The Muscle Study Group (MSG), and The British Myology Society (BMS), and past-chair (2013–2014) of the Emerging EULAR Network (EMEUNET). He is a member of the Editorial Board of the journals RMD Open, Best Practice & Research: Clinical Rheumatology, and Acta Reumatológica Portuguesa.
- Myositis/neuromuscular diseases
- Musculoskeletal Imaging
- Clinical trials